Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma (PICASSO)

Next Previous
Search
Trial Profile

A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma (PICASSO)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palifosfamide (Primary) ; Doxorubicin
  • Indications Chondrosarcoma; Dermatofibrosarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Kaposi's sarcoma; Liposarcoma; Osteosarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms PICASSO
  • Sponsors Alaunos Therapeutics

Most Recent Events

  • 29 Jan 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Apr 2014.
  • 13 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
  • 17 Jul 2013 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top